Drug
Acetylcarnitine
Acetylcarnitine is a pharmaceutical drug with 4 clinical trials. Historical success rate of 50.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 2 completed trials
Completion Rate
50%(2/4)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Terminated
2(50%)
Phase Distribution
Ph phase_3
2
50%
Ph phase_2
1
25%
Ph phase_4
1
25%
Phase Distribution
0
Early Stage
1
Mid Stage
3
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
2(50.0%)
Phase 4Post-market surveillance
1(25.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
50.0%
2 of 4 finished
Non-Completion Rate
50.0%
2 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(2)
Terminated(2)
Detailed Status
Terminated2
Completed2
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
50.0%
Most Advanced
Phase 4
Trials by Phase
Phase 21 (25.0%)
Phase 32 (50.0%)
Phase 41 (25.0%)
Trials by Status
terminated250%
completed250%
Recent Activity
0 active trials
Showing 4 of 4
terminatedphase_2
A Pilot Study Investigating the Effects of Acetyl-L-Carnitine and Vincristine-Induced Neuropathy in Pediatric Patients With ALL
NCT02598622
terminatedphase_3
Acetyl-L-carnitine in Combination With a Cisplatin-containing Chemotherapy as First Line Treatment of Advanced or Metastatic Non Small Cell Lung Cancer
NCT01379976
completedphase_3
Clinical Study on Acetyl-L-Carnitine
NCT01526564
completedphase_4
Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α2b Plus Ribavirin
NCT01913964
Clinical Trials (4)
Showing 4 of 4 trials
NCT02598622Phase 2
A Pilot Study Investigating the Effects of Acetyl-L-Carnitine and Vincristine-Induced Neuropathy in Pediatric Patients With ALL
NCT01379976Phase 3
Acetyl-L-carnitine in Combination With a Cisplatin-containing Chemotherapy as First Line Treatment of Advanced or Metastatic Non Small Cell Lung Cancer
NCT01526564Phase 3
Clinical Study on Acetyl-L-Carnitine
NCT01913964Phase 4
Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α2b Plus Ribavirin
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4